Inolimomab, with the CAS number 152981-31-2, is a monoclonal antibody that has been investigated primarily for its immunomodulatory properties. It is designed to target specific immune pathways, making it a candidate for therapeutic applications in autoimmune diseases and conditions characterized by excessive immune responses. As a monoclonal antibody, Inolimomab is produced using recombinant DNA technology, allowing for a high degree of specificity and consistency in its action. The substance typically exhibits characteristics common to monoclonal antibodies, such as high molecular weight, stability under appropriate storage conditions, and the ability to bind selectively to its target antigen. Its mechanism of action often involves modulation of immune cell activity, potentially leading to reduced inflammation and altered immune responses. Clinical studies may focus on its efficacy, safety profile, and pharmacokinetics, which are crucial for determining its therapeutic potential. As with any biopharmaceutical, understanding its characteristics is essential for optimizing its use in clinical settings.

Inolimomab

152981-31-2: Inolimomab, with the CAS number 152981-31-2, is a monoclonal antibody that has been investigated primarily for its immunomodulatory properties. It is designed to target specific immune pathways, making it a candidate for therapeutic applications in autoimmune diseases and conditions characterized by excessive immune responses. As a monoclonal antibody, Inolimomab is produced using recombinant DNA technology, allowing for a high degree of specificity and consistency in its action. The substance typically exhibits characteristics common to monoclonal antibodies, such as high molecular weight, stability under appropriate storage conditions, and the ability to bind selectively to its target antigen. Its mechanism of action often involves modulation of immune cell activity, potentially leading to reduced inflammation and altered immune responses. Clinical studies may focus on its efficacy, safety profile, and pharmacokinetics, which are crucial for determining its therapeutic potential. As with any biopharmaceutical, understanding its characteristics is essential for optimizing its use in clinical settings.

<p>A humanized anti-interleukin-2 receptor (IL-2R) α chain monoclonal antibody.</p>

Inolimomab is a monoclonal antibody targeting CD25 (IL-2R α chain) for studying acute graft-versus-host disease (aGVHD).

CAS 152981-31-2

Inolimomab

Inolimomab

Ref: 3D-CLA1102

Inolimomab

Ref: TM-T77036